Fda approves first pd l1 inhibitor for bladder cancer

1
FDA Approves First PD-L1 Inhibitor for Bladder
Cancer
2

• Swiss pharma Roches Tecentriq (atezolizumab)
  became the first PD-L1 inhibitor to be approved
  by US Food and Drug Administration (FDA).

3

• Tecentriq is approved for the treatment of a
  bladder cancer, urothelial carcinoma. It is the
  most common type of bladder cancer. Tecentriq is
  marketed by Genentech (California). Tecentriq is
  a fully humanized monoclonal antibody which
  interfere with the proteins called the programmed
  death ligand 1 (PD-L1).

4

• The PD-L1 is expressed on the tumour cells and
  the Tecentriq target them and prevent them from
  binding to the PD-1 present on the T-cells
  surface. Finally, activating the T-cells to
  detect and attack the malignant cells.

5

• Tecentriq is the first FDA approved PD-L1
  inhibitor and by blocking the interactions of
  PD-L1 proteins with their receptors it helps the
  bodys immune system to fight cancer. Tecentriq
  underwent a single arm clinical trial involving
  310 patients.

6

• The trial examined the percentage of patients who
  experienced complete or partial shrinkage of the
  tumors. 14.8 of the patients experienced a
  partial shrinkage of their tumors, this effect
  lasted for 2.1 to 13.8 months.

7
Mechanism of action of Tecentriq
8

• Difference in the effect based on positive and
  negative expression of the PD-L1 protein on tumor
  infiltrating immune cells of patients was also
  examined. Patients classified as positive for
  PD-L1 expression 26 of them experienced a tumor
  response.

9

• The most common side effects of treatment with
  Tencentriq were fatigue, decreased appetite,
  nausea, urinary tract infection fever and
  constipation. Immune mediated side effects were
  also noted that involved vital organs like lungs,
  colon,endocrine system.

10
(No Transcript)
11

• Tecentriq is approved for the treatment of
  patients with locally advanced or metastatic
  urothelial carcinoma whose disease has worsened
  during or following platinum-containing
  chemotherapy, or within 12 months of receiving
  platinum-containing chemotherapy, either before
  (neoadjuvant) or after (adjuvant) surgical
  treatment.

12

• Urothelial carcinoma is the most common type of
  bladder cancer and occurs in the urinary tract
  system, involving the bladder and related organs.
  The National Cancer Institute (NCI) estimates
  76,960 new cases of bladder cancer and 16,390
  deaths from the disease in 2016.

13

• To Know More Update, Visit Us

http//medgenera.com/